Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 43 positions · Total reported value $2.00B · Top-10 concentration 77.4% · Updated 2026-10-05

Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Casdin Capital disclosed 43 equity positions with a combined reported value of $2.00B. The filing implies a focused portfolio: its ten largest positions account for 77.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RVMD ($482.68M), RLAY ($300.02M), WGS ($254.50M). By sector, the heaviest allocations are Health Care 94.2%, Industrials 5.7%. Versus the prior quarter, allocation shifted toward Health Care (+5.1pp) and away from Technology (-1.0pp), Industrials (-4.2pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q2 2026 were PBLS ($17.67M), SION ($17.60M), SRPT ($8.45M).

Of the 3 positions fully exited versus the prior quarter, the largest were QGEN ($14.41M), TEM ($13.30M), MLTX ($8.39M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $17.67M
  • SION SIONNA THERAPEUTICS INC · $17.60M
  • SRPT SAREPTA THERAPEUTICS INC · $8.45M
  • QURE UNIQURE NV · $6.91M
  • EDIT EDITAS MEDICINE INC · $1.44M
  • KARD KARDIGAN INC · $1.19M

Fully Exited (vs previous quarter)

  • QGEN QIAGEN N.V. · prev qtr: $14.41M
  • TEM TEMPUS AI INC · prev qtr: $13.30M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $8.39M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view Casdin Capital demonstrates a bullish stance on biotechnology and pharmaceutical innovation, with a concentrated portfolio heavily weighted toward healthcare (80% of top holdings) and active position adjustments suggesting confidence in specialized therapeutic areas. 2. Key moves (what was added/reduced, by how much) Significant additions: RLAY (+11.2%), WGS (+23.3%), DNLI (+11.1%), NGNE (+8.8%); notable reduction: BLFS (-21.9%); others held steady. 3. Portfolio structure (passive/active, sector bias, risk appetite) Actively managed with concentrated positions (top 10 holdings = 84.74% of portfolio), strong healthcare bias (biotech/pharma focus), and high risk tolerance through specialized growth investments. 4. Per-holding one-liner: - RVMD: Revolution Medicines - cancer-focused biotechnology (verified) - RLAY: Relay Therapeutics - AI-driven drug discovery (verified) - WGS: Genedx Holdings - genetic testing diagnostics (verified) - BLFS: Biolife Solutions - biological product storage (verified) - ILMN: Illumina - genetic sequencing technology (verified) - LAB: Standard Biotools - laboratory equipment (verified) - GPCR: Structure Therapeutics - GPCR drug discovery (verified) - DNLI: Denali Therapeutics - neuroscience biotech (verified) - NGNE: Neurogene - neurological gene therapy (verified) - BEAM: Beam Therapeutics - gene editing therapeutics (verified) 5. One-sentence style summary Casdin Capital actively concentrates on innovative biotechnology and pharmaceutical companies, making significant additions to drug discovery and gene therapy positions while selectively reducing exposure to biological storage services.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 94.2%
Other 0.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.58M $482.68M 24.16%
24.16%
Hold
2 16.04M $300.02M 15.02%
15.02%
Add
3 3.71M $254.50M 12.74%
12.74%
Add
4 4.66M $131.46M 6.58%
6.58%
Reduce
5 530.00K $93.19M 4.67%
4.67%
Hold
6 88.78M $73.04M 3.66%
3.66%
Hold
7 1.18M $63.06M 3.16%
3.16%
Hold
8 2.04M $52.60M 2.63%
2.63%
Add
9 1.55M $48.60M 2.43%
2.43%
Add
10 1.35M $46.33M 2.32%
2.32%
Hold
11 1.05M $40.26M 2.02%
2.02%
Reduce
12 665.00K $36.58M 1.83%
1.83%
Add
13 2.55M $34.17M 1.71%
1.71%
Add
14 480.00K $32.77M 1.64%
1.64%
Add
15 185.00K $27.76M 1.39%
1.39%
Reduce
16 843.86K $25.18M 1.26%
1.26%
Add
17 700.00K $24.27M 1.22%
1.22%
Hold
18 75.00K $22.58M 1.13%
1.13%
Hold
19 3.25M $22.13M 1.11%
1.11%
Hold
20 1.55M $20.12M 1.01%
1.01%
Hold
21 553.27K $18.53M 0.93%
0.93%
Hold
22 645.69K $17.67M 0.89%
0.89%
New
23 400.00K $17.60M 0.88%
0.88%
New
24 276.31K $16.23M 0.81%
0.81%
Hold
25 1.25M $14.38M 0.72%
0.72%
Add
26 3.17M $11.69M 0.58%
0.58%
Hold
27 973.26K $11.28M 0.56%
0.56%
Hold
28 50.00K $10.60M 0.53%
0.53%
Hold
29 470.00K $8.45M 0.42%
0.42%
New
30 150.00K $6.91M 0.35%
0.35%
New
31 355.00K $6.01M 0.30%
0.30%
Hold
32 75.00K $5.25M 0.26%
0.26%
Hold
33 65.00K $4.75M 0.24%
0.24%
Hold
34 186.01K $4.50M 0.23%
0.23%
Hold
35 1.23M $3.01M 0.15%
0.15%
Hold
36 148.33K $2.43M 0.12%
0.12%
Hold
37 282.31K $2.15M 0.11%
0.11%
Hold
38 445.00K $1.44M 0.07%
0.07%
New
39 723.77K $1.22M 0.06%
0.06%
Hold
40 50.00K $1.19M 0.06%
0.06%
New
41 165.32K $606.74K 0.03%
0.03%
Hold
42 36.49K $361.65K 0.02%
0.02%
Hold
43 361.97K $267.53K 0.01%
0.01%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Low-confidence forecast This fund replaces about 21% of its Top-10 each quarter and backtests at F1 80% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (41 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 2.3 · Top-10 turnover 21%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2016-Q2 70% 70% 70% EPZM · FMI · LOXO · AGIO · SAGE · ALNY · BLUE · BPMC · MYOK · ONCE ONCE · AGIO · FMI · GBT · LOXO · BPMC · BLUE · EVH · ALNY · KITE
2016-Q3 80% 80% 80% AGIO · ONCE · FMI · GBT · LOXO · BPMC · BLUE · EVH · ALNY · KITE AGIO · SAGE · FMI · EVH · BPMC · LOXO · GNMK · ONCE · GBT · KITE
2016-Q4 80% 80% 80% AGIO · SAGE · EVH · FMI · BPMC · GNMK · LOXO · GBT · ONCE · KITE SAGE · LOXO · AGIO · FMI · EVH · BPMC · ONCE · GNMK · BLUE · VYGR
2017-Q1 90% 90% 90% SAGE · LOXO · AGIO · FMI · EVH · BPMC · GNMK · ONCE · VYGR · BLUE SAGE · FMI · LOXO · AGIO · BPMC · EVH · EPZM · ONCE · VYGR · GNMK
2017-Q2 70% 70% 70% SAGE · FMI · LOXO · AGIO · EVH · BPMC · EPZM · ONCE · VYGR · GNMK LOXO · SAGE · FMI · BPMC · EVH · AGIO · SGMOQ · CLVSQ · XBI · ONCE
2017-Q3 60% 60% 60% LOXO · SAGE · FMI · BPMC · SGMOQ · CLVSQ · AGIO · XBI · EVH · ONCE LOXO · MYOK · ALNY · SGMOQ · BPMC · BLUE · FMI · KITE · ONCE · AGIO
2017-Q4 80% 80% 80% LOXO · ALNY · MYOK · BLUE · SGMOQ · KITE · BPMC · ONCE · FMI · VYGR SAGE · FMI · LOXO · BPMC · BLUE · ALNY · MYOK · SGMOQ · GBT · VYGR
2018-Q1 80% 80% 80% SAGE · FMI · LOXO · BLUE · ALNY · BPMC · MYOK · SGMOQ · GBT · VYGR LOXO · FMI · SAGE · BPMC · ONCE · AGIO · ALNY · GBT · MYOK · SGMOQ
2018-Q2 70% 70% 70% LOXO · FMI · SAGE · ONCE · AGIO · BPMC · GBT · ALNY · FATE · MYOK FMI · SAGE · MYOK · ONCE · BLUE · AGIO · FATE · CDXS · MGTA · ALNY
2018-Q3 60% 60% 60% FMI · ONCE · MYOK · SAGE · AGIO · BLUE · CDXS · FATE · ALNY · MGTA LOXO · BPMC · MYOK · AGIO · SAGE · BLFS · FATE · NVTAQ · BLUE · ONCE
2018-Q4 90% 90% 90% LOXO · BPMC · MYOK · BLFS · AGIO · SAGE · FATE · BLUE · NVTAQ · ONCE LOXO · MYOK · BPMC · CDXS · ONCE · BLUE · FATE · SAGE · BLFS · NVTAQ
2019-Q1 80% 80% 80% LOXO · BPMC · MYOK · ONCE · BLUE · CDXS · BLFS · FATE · SAGE · ALNY ONCE · BPMC · MYOK · SAGE · BLUE · NVTAQ · FATE · MGTA · BLFS · ALNY
2019-Q2 80% 80% 80% ONCE · MYOK · BPMC · SAGE · BLUE · NVTAQ · FATE · ALNY · MGTA · BLFS ONCE · NVTAQ · BPMC · CDXS · SAGE · MYOK · FATE · SRPT · BLUE · ALNY
2019-Q3 90% 90% 90% CDXS · NVTAQ · BPMC · ONCE · SAGE · MYOK · SRPT · FATE · ALNY · BLUE ONCE · NVTAQ · CDXS · BPMC · SRPT · MYOK · BLUE · SAGE · ALNY · BLFS
2019-Q4 70% 70% 70% ONCE · NVTAQ · CDXS · SRPT · BPMC · BLUE · MYOK · SAGE · ALNY · BLFS SRPT · BLUE · CDXS · BPMC · MYOK · ALNY · NVTAQ · CNST · BOLD · FATE
2020-Q1 90% 90% 90% SRPT · BLUE · CDXS · BPMC · MYOK · ALNY · NVTAQ · CNST · BOLD · FATE BPMC · SRPT · ALNY · FATE · CDXS · BLUE · NVTAQ · MYOK · AGIO · CNST
2020-Q2 90% 90% 90% BPMC · SRPT · ALNY · FATE · CDXS · BLUE · NVTAQ · MYOK · AGIO · TWST NVTAQ · BPMC · FATE · SRPT · MYOK · ALNY · BLFS · BLUE · AGIO · CDXS
2020-Q3 80% 80% 80% NVTAQ · BPMC · FATE · BLFS · ALNY · SRPT · MYOK · BLUE · AGIO · CDXS NVTAQ · BLFS · RLAY · BPMC · FATE · MYOK · ALNY · TWST · SRPT · AGIO
2020-Q4 70% 70% 70% NVTAQ · BLFS · RLAY · BPMC · FATE · MYOK · ALNY · TWST · SRPT · AGIO NVTAQ · BLFS · FATE · EXAS · BPMC · RLAY · TWST · PACB · DNLI · AGIO
2021-Q1 90% 90% 90% NVTAQ · BLFS · FATE · EXAS · BPMC · RLAY · TWST · PACB · AGIO · DNLI NVTAQ · EXAS · FATE · BLFS · PACB · BPMC · ALNY · TWST · RLAY · AGIO
2021-Q2 80% 80% 80% NVTAQ · EXAS · FATE · BLFS · PACB · BPMC · ALNY · TWST · AGIO · RLAY NVTAQ · BLFS · FATE · EXAS · VERV · PACB · ALNY · BPMC · TWST · DNLI
2021-Q3 80% 80% 80% NVTAQ · BLFS · EXAS · FATE · VERV · ALNY · PACB · BPMC · TWST · DNLI NVTAQ · BLFS · EXAS · PACB · FATE · ALNY · MXCT · BPMC · SLGC · VERV
2021-Q4 90% 90% 90% NVTAQ · BLFS · EXAS · PACB · FATE · ALNY · MXCT · BPMC · SLGC · VERV BLFS · EQRX · FATE · NVTAQ · ALNY · BPMC · PACB · EXAS · SLGC · MXCT
2022-Q1 90% 90% 90% BLFS · EQRX · FATE · NVTAQ · PACB · ALNY · BPMC · EXAS · SLGC · MXCT BLFS · ALNY · EQRX · FATE · RLAY · SLGC · BPMC · MXCT · NVTAQ · EXAS
2022-Q2 80% 80% 80% BLFS · EQRX · ALNY · FATE · RLAY · SLGC · BPMC · MXCT · NVTAQ · EXAS EQRX · ALNY · BLFS · RLAY · MXCT · BPMC · SLGC · FATE · SRPT · VERV
2022-Q3 80% 80% 80% EQRX · ALNY · BLFS · RLAY · MXCT · BPMC · SLGC · FATE · VERV · RVMD EQRX · BLFS · SRPT · ALNY · BPMC · VERV · RLAY · ILMN · MXCT · RVMD
2022-Q4 100% 100% 100% EQRX · BLFS · SRPT · ALNY · BPMC · RLAY · VERV · ILMN · MXCT · RVMD SRPT · BLFS · EQRX · ALNY · ILMN · BPMC · RVMD · MXCT · RLAY · VERV
2023-Q1 60% 60% 60% SRPT · BLFS · EQRX · ALNY · ILMN · BPMC · RVMD · MXCT · RLAY · VERV BLFS · RLAY · EQRX · ILMN · ALNY · NTLA · PLRX · RVMD · EXAS · WGS
2023-Q2 70% 70% 70% BLFS · RLAY · EQRX · ILMN · NTLA · PLRX · ALNY · WGS · RVMD · EXAS BLFS · SRPT · RLAY · EQRX · ALNY · NTLA · RVMD · EXAS · VERV · GPCR
2023-Q3 90% 90% 90% BLFS · SRPT · RLAY · EQRX · NTLA · ALNY · RVMD · GPCR · EXAS · VERV SRPT · BLFS · EQRX · GPCR · RLAY · RVMD · VERV · NTLA · EXAS · SLGC
2023-Q4 80% 80% 80% SRPT · BLFS · EQRX · GPCR · RLAY · RVMD · VERV · NTLA · EXAS · SLGC RVMD · BLFS · SRPT · RLAY · NTLA · VERV · ALNY · SLGC · EXAS · BPMC
2024-Q1 70% 70% 70% RVMD · BLFS · SRPT · RLAY · NTLA · VERV · ALNY · SLGC · EXAS · BPMC RVMD · LAB · BLFS · SRPT · RLAY · ALNY · RNAM · GPCR · EXAS · VERV
2024-Q2 70% 70% 70% RVMD · LAB · BLFS · SRPT · RLAY · ALNY · RNAM · GPCR · EXAS · VERV BLFS · RVMD · SRPT · LAB · WGS · RNAM · RLAY · ILMN · NTLA · ALNY
2024-Q3 90% 90% 90% BLFS · SRPT · RVMD · LAB · WGS · RNAM · ILMN · RLAY · NTLA · ALNY BLFS · RVMD · WGS · LAB · SRPT · ILMN · RNAM · RLAY · ALNY · EXAS
2024-Q4 90% 90% 90% BLFS · RVMD · WGS · LAB · SRPT · ILMN · RNAM · RLAY · NTLA · EXAS WGS · BLFS · RVMD · SRPT · LAB · ILMN · RNAM · CDXS · RLAY · EXAS
2025-Q1 70% 70% 70% WGS · BLFS · RVMD · SRPT · LAB · ILMN · RNAM · CDXS · RLAY · EXAS WGS · BLFS · RVMD · LAB · RNAM · SRPT · ILMN · ALNY · BPMC · BEAM
2025-Q2 70% 70% 70% WGS · BLFS · RVMD · LAB · RNAM · SRPT · ILMN · ALNY · BEAM · BPMC WGS · BLFS · RVMD · LAB · ILMN · RNAM · VERV · RLAY · ALNY · GPCR
2025-Q3 90% 90% 90% WGS · BLFS · RVMD · LAB · ILMN · RNAM · VERV · RLAY · GPCR · ALNY WGS · BLFS · RVMD · LAB · RNAM · RLAY · ILMN · GPCR · BEAM · ALNY
2025-Q4 90% 90% 90% WGS · BLFS · RVMD · LAB · RNAM · RLAY · GPCR · ILMN · BEAM · TEM WGS · RVMD · BLFS · LAB · RLAY · GPCR · ILMN · RNAM · BEAM · GH
2026-Q1 80% 80% 80% WGS · RVMD · BLFS · LAB · RLAY · GPCR · ILMN · RNAM · BEAM · GH RVMD · WGS · RLAY · BLFS · LAB · ILMN · GPCR · TXG · DNLI · BEAM
2026-Q2 ★ 80% 80% 80% RVMD · WGS · RLAY · BLFS · LAB · ILMN · TXG · GPCR · DNLI · GH RVMD · RLAY · WGS · BLFS · ILMN · LAB · GPCR · DNLI · NGNE · BEAM

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Casdin Capital buy in 2026-Q2?

In its 2026-Q2 13F filing, Casdin Capital reported 43 equity positions worth $2.00B in aggregate; its largest disclosed positions were RVMD ($482.68M), RLAY ($300.02M), WGS ($254.50M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $2.00B of long equity holdings across 43 positions as of 2026-Q2. Top-10 holdings account for 77.4% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →